KBY Biotech Indexv0.0.34
Search
← Pipeline|NAT-IIT-211

NAT-IIT-211

Phase 3
By Natl Taiwan Univ Hosp
Source: Trial-derived·Trials: 1
Modality
Small Molecule
MOA
EGFRi
Target
AuroraA
Pathway
Wnt
Hemophilia A
Development Pipeline
Preclinical
~Jul 2019
→ ~Oct 2020
Phase 1
~Jan 2021
→ ~Apr 2022
Phase 2
~Jul 2022
→ ~Oct 2023
Phase 3
Jan 2024
Phase 3Current
NCT07860186
397 pts·Hemophilia A
2024-01→TBD·Active
397 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-11-115mo agoConference· Hemophilia A
Trial Timeline
2024Q2Q3Q42025Q2Q3Q4
P3
Active
Catalysts
Conference
2025-11-11 · 5mo ago
Hemophilia A
Active|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT07860186Phase 3Hemophilia AActive397SeizFreq
Competitors (10)
DrugCompanyPhaseTargetMOA
NiranesiranJohnson & JohnsonPhase 2KIF18AEGFRi
JNJ-5094Johnson & JohnsonPhase 2/3GIP-REGFRi
MotarapivirGSKPreclinicalAuroraAIL-23i
GSK-2051GSKPhase 1PSMAEGFRi
BAY-8733BayerPreclinicalAuroraABETi
GIL-8529Gilead SciencesPhase 1/2JAK1EGFRi
BNT-8090BioNTechPhase 2AuroraAPD-L1i
ARG-6988ArgenxPreclinicalAuroraACDK2i
207-2754Samsung BiologicsPhase 1/2KRASG12DEGFRi
MavuratamabBlueprint MedicinesNDA/BLABETEGFRi